Scinovex
review Open AccessTop 1% cited

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Nature Reviews Drug Discovery · 2020 · Vol. 19(3) · pp. 149–150
Guangdi LiErik De Clercq
SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Outbreaks ResearchRepurposingCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakMedicineOutbreakDrug repositioningClinical trialCoronavirusCoronavirus Infections

MeSH terms

BetacoronavirusCOVID-19SARS-CoV-2COVID-19 Drug TreatmentAdenosine MonophosphateAlanineAntiviral AgentsHepatitis BHepatitis CHumansInfluenza, HumanNucleosidesPneumonia, ViralPolyethylene GlycolsProtease Inhibitors

Funding

  • National Natural Science Foundation of China
  • Central South University
  • National Science and Technology Major Project
Citations
1,828
FWCI
44.24
field-weighted impact
References
7
Percentile
100%
vs. same field & year
Citations per year
Cited by
The SARS-CoV-2 main protease as drug target
Bioorganic & Medicinal Chemistry Letters · 2020 · 785 citations
The hallmarks of COVID-19 disease
PLoS Pathogens · 2020 · 480 citations
References
Coronaviruses — drug discovery and therapeutic options
Nature Reviews Drug Discovery · 2016 · 1,783 citations
Approved Antiviral Drugs over the Past 50 Years
Clinical Microbiology Reviews · 2016 · 1,404 citations
First Case of 2019 Novel Coronavirus in the United States
New England Journal of Medicine · 2020 · 6,361 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.